SI2822947T1 - Argininske soli TLR7 agonista - Google Patents

Argininske soli TLR7 agonista

Info

Publication number
SI2822947T1
SI2822947T1 SI201330288A SI201330288A SI2822947T1 SI 2822947 T1 SI2822947 T1 SI 2822947T1 SI 201330288 A SI201330288 A SI 201330288A SI 201330288 A SI201330288 A SI 201330288A SI 2822947 T1 SI2822947 T1 SI 2822947T1
Authority
SI
Slovenia
Prior art keywords
tlr7 agonist
arginine salts
arginine
salts
tlr7
Prior art date
Application number
SI201330288A
Other languages
English (en)
Inventor
Stephanie Kay Dodd
Siddartha Jain
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of SI2822947T1 publication Critical patent/SI2822947T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
SI201330288A 2012-03-07 2013-03-07 Argininske soli TLR7 agonista SI2822947T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261608011P 2012-03-07 2012-03-07
EP13708142.8A EP2822947B1 (en) 2012-03-07 2013-03-07 Arginine salts of a tlr7 agonist
PCT/EP2013/054548 WO2013131985A1 (en) 2012-03-07 2013-03-07 Immunologically useful arginine salts

Publications (1)

Publication Number Publication Date
SI2822947T1 true SI2822947T1 (sl) 2016-10-28

Family

ID=47843276

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201330288A SI2822947T1 (sl) 2012-03-07 2013-03-07 Argininske soli TLR7 agonista

Country Status (18)

Country Link
US (1) US9320748B2 (sl)
EP (1) EP2822947B1 (sl)
JP (1) JP6325986B2 (sl)
CN (1) CN104203946B (sl)
AU (1) AU2013229466A1 (sl)
CA (1) CA2865759C (sl)
CY (1) CY1118091T1 (sl)
DK (1) DK2822947T3 (sl)
ES (1) ES2597755T3 (sl)
HR (1) HRP20161354T1 (sl)
HU (1) HUE030175T2 (sl)
LT (1) LT2822947T (sl)
MX (1) MX346678B (sl)
PL (1) PL2822947T3 (sl)
PT (1) PT2822947T (sl)
RU (1) RU2014140336A (sl)
SI (1) SI2822947T1 (sl)
WO (1) WO2013131985A1 (sl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012004806B8 (pt) 2009-09-02 2022-10-04 Novartis Ag composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
US20120177681A1 (en) 2010-09-01 2012-07-12 Manmohan Singh Formulation of immunopotentiators
AU2012222883A1 (en) 2011-03-02 2013-10-17 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
JP6345603B2 (ja) 2012-03-08 2018-06-20 ノバルティス アーゲー 追加免疫ワクチンのアジュバント化された処方物
CN112521464A (zh) 2014-03-26 2021-03-19 葛兰素史密丝克莱恩生物有限公司 突变型葡萄球菌抗原
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
US20230110516A1 (en) * 2020-03-01 2023-04-13 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
US20220280482A1 (en) * 2021-03-06 2022-09-08 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699474B1 (en) 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
DE69333110T2 (de) 1992-03-02 2004-05-06 Chiron S.P.A. Mit dem cytotoxin von helicobacter pylori assoziiertes, immunodominantes antigen verwendbar in impfstoffen und zur diagnose
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
JPH10502365A (ja) 1994-07-01 1998-03-03 リカン・リミテッド ヘリコバクタータンパク質およびワクチン
PT909323E (pt) 1996-01-04 2007-06-04 Novartis Vaccines & Diagnostic ''bacterioferritina de helicobacter pilori''
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
AU2001276619A1 (en) 2000-07-03 2002-01-14 Chiron S.P.A. Immunisation against chlamydia pneumoniae
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
AU2002366592B2 (en) 2001-12-12 2008-01-10 Novartis Vaccines And Diagnostics S.R.L. Immunisation against Chlamydia trachomatis
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
SI1549338T1 (sl) 2002-10-11 2011-04-29 Novartis Vaccines & Diagnostic Polipeptidna cepiva za ĺ iroko zaĺ äśito pred hipervirulentnimi miningokoknimi rodovi
MXPA05013260A (es) 2003-06-26 2006-03-09 Chiron Corp Composiciones inmunogenicas para chlamydia trachomatis.
WO2005084306A2 (en) 2004-03-02 2005-09-15 Chiron Corporation Immunogenic compositions for chlamydia pneunomiae
DK2351772T3 (en) 2005-02-18 2016-09-05 Glaxosmithkline Biologicals Sa Proteins and nucleic acids from meningitis / sepsis-associated Escherichia coli
US8062644B2 (en) 2005-02-18 2011-11-22 Novartis Vaccines & Diagnostics Srl. Immunogens from uropathogenic Escherichia coli
RU2007146137A (ru) 2005-05-12 2009-06-27 Новартис Вэксинес Энд Дайэгностикс, Инк. (Us) Иммуногенные композиции на основе chlamydia trachomatis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
EP1976557A2 (en) 2005-12-22 2008-10-08 Novartis Vaccines and Diagnostics S.r.l. Chlamydial antigens
JP2010500399A (ja) 2006-08-16 2010-01-07 ノバルティス アーゲー 尿路病原性大腸菌由来の免疫原
EP2200642B1 (en) 2007-10-19 2012-04-18 Novartis AG Meningococcal vaccine formulations
EP2419129A2 (en) 2009-04-14 2012-02-22 Novartis AG Compositions for immunising against staphylococcus aerus
CN102481354A (zh) 2009-06-01 2012-05-30 诺华有限公司 肺炎球菌RrgB分化枝的组合物
US9517263B2 (en) * 2009-06-10 2016-12-13 Glaxosmithkline Biologicals Sa Benzonaphthyridine-containing vaccines
CN102596240B (zh) 2009-08-27 2015-02-04 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
JO3257B1 (ar) * 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
BR112012004806B8 (pt) * 2009-09-02 2022-10-04 Novartis Ag composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
US20120177681A1 (en) * 2010-09-01 2012-07-12 Manmohan Singh Formulation of immunopotentiators
US10286056B2 (en) 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
RU2014112343A (ru) * 2011-09-01 2015-10-10 Новартис Аг Оставы антигенов staphylococcus aureus, содержащие адъюванты

Also Published As

Publication number Publication date
EP2822947B1 (en) 2016-08-03
PL2822947T3 (pl) 2017-01-31
HRP20161354T1 (hr) 2016-12-02
MX346678B (es) 2017-03-29
CY1118091T1 (el) 2017-06-28
DK2822947T3 (en) 2016-09-19
AU2013229466A1 (en) 2014-09-04
JP2015511957A (ja) 2015-04-23
US9320748B2 (en) 2016-04-26
JP6325986B2 (ja) 2018-05-16
MX2014010423A (es) 2014-09-22
CN104203946B (zh) 2017-03-22
CN104203946A (zh) 2014-12-10
ES2597755T3 (es) 2017-01-20
EP2822947A1 (en) 2015-01-14
CA2865759C (en) 2020-07-21
PT2822947T (pt) 2016-09-26
WO2013131985A1 (en) 2013-09-12
RU2014140336A (ru) 2016-04-27
LT2822947T (lt) 2016-10-10
CA2865759A1 (en) 2013-09-12
US20150125475A1 (en) 2015-05-07
HUE030175T2 (en) 2017-04-28

Similar Documents

Publication Publication Date Title
PL2822947T3 (pl) Sole argininowe agonisty TLR7
EP2970081A4 (en) SALTS OF TREPROSTINIL
GB201304499D0 (en) Carcainium Salts
HK1195770A1 (en) Amorphous solid salts of cobicistat (gs-9350) (cobicistat)(gs-9350)
HK1192562A1 (zh) 取代的苯甲酰胺衍生物
IL231269B (en) Preparations for the treatment of HIV
ZA201409497B (en) Tetrahydroquinazolinone derivatives as parp inhibitors
ZA201409327B (en) Solid forms of a pyrido-pyrimidinium inner salt
EP2785766A4 (en) HYDROXYPOLYAMINSALZE
HK1200454A1 (zh) 琥珀酸鹽的晶形
ZA201307229B (en) Prodrugs of d-isoglutamyl-[d/l]- tryprophan
EP2782902A4 (en) DERIVATIVES FROM PHENOXYISOBUTTERIC ACID
HRP20171362T1 (hr) Soli benzotiazolonskog spoja koje služe kao agonist beta-2-adrenoceptora
PL2760822T3 (pl) Sole desfezoterodyny
EP2702991A4 (en) COMPOSITION OF ENTACOPONE
ZA201308872B (en) Use of a dinitromethane salt
ZA201205358B (en) Use of a salt of bistetrazolylamine
GB201100332D0 (en) Monty Izofit
GB201106819D0 (en) Novel salts
GB201209895D0 (en) Use of a composition
GB201219868D0 (en) Facilitating completion of a form
GB201204590D0 (en) Prodrugs of thiazolamine compounds